These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 19563314)

  • 1. Policy challenges of nanomedicine for Australia's PBS.
    Faunce TA
    Aust Health Rev; 2009 May; 33(2):258-67. PubMed ID: 19563314
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Researching safety and cost-effectiveness in the life cycle of nanomedicine.
    Faunce T; Shats K
    J Law Med; 2007 Aug; 15(1):128-35. PubMed ID: 17902495
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evidence-based decision-making within Australia's pharmaceutical benefits scheme.
    Lopert R
    Issue Brief (Commonw Fund); 2009 Jul; 60():1-13. PubMed ID: 19639714
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transparency in pricing arrangements for medicines listed on the Australian Pharmaceutical Benefits Scheme.
    Robertson J; Walkom EJ; Henry DA
    Aust Health Rev; 2009 May; 33(2):192-9. PubMed ID: 19563308
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug policy down under: Australia's pharmaceutical benefits scheme.
    Duckett SJ
    Health Care Financ Rev; 2004; 25(3):55-67. PubMed ID: 15229996
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Australian Pharmaceutical Benefits Scheme data collection: a practical guide for researchers.
    Mellish L; Karanges EA; Litchfield MJ; Schaffer AL; Blanch B; Daniels BJ; Segrave A; Pearson SA
    BMC Res Notes; 2015 Nov; 8():634. PubMed ID: 26526064
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Balancing health and industrial policy objectives in the pharmaceutical sector: lessons from Australia.
    Morgan S; McMahon M; Greyson D
    Health Policy; 2008 Aug; 87(2):133-45. PubMed ID: 18295927
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Costs of paying higher prices for equivalent effects on the Pharmaceutical Benefits Scheme.
    Karnon J; Edney L; Sorich M
    Aust Health Rev; 2017 Mar; 41(1):1-6. PubMed ID: 26954612
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A survey of reimbursement practices of private health insurance companies for pharmaceuticals not covered under the Pharmaceutical Benefits Scheme 2008.
    Lingaratnam SM; Kirsa SW; Mellor JD; Jackson J; Crellin W; Fitzsimons M; Zalcberg JR
    Aust Health Rev; 2011 May; 35(2):204-10. PubMed ID: 21612735
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulatory aspects on nanomedicines.
    Sainz V; Conniot J; Matos AI; Peres C; Zupancic E; Moura L; Silva LC; Florindo HF; Gaspar RS
    Biochem Biophys Res Commun; 2015 Dec; 468(3):504-10. PubMed ID: 26260323
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Challenges for Australia's Bio/Nanopharma Policies: trade deals, public goods and reference pricing in sustainable industrial renewal.
    Faunce TA
    Aust New Zealand Health Policy; 2007 Jun; 4():9. PubMed ID: 17543114
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Misuse of the Precautionary Principle in Justifying Australia's Ban on the Sale of Nicotine Vaping Products.
    Morphett K; Hall W; Gartner C
    Nicotine Tob Res; 2021 Jan; 23(1):14-20. PubMed ID: 32909044
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Pharmaceutical Benefits Scheme and implications for paediatric prescribing.
    Sinha Y; Brien JA; Craig JC
    J Paediatr Child Health; 2009 Jun; 45(6):351-7. PubMed ID: 19490409
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A perspective on Australia's National Medicines Policy.
    Tett SE
    Can J Clin Pharmacol; 2004; 11(1):e28-38. PubMed ID: 15226524
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Challenges to pharmaceutical policymaking: lessons from Australia's national medicines policy.
    Lipworth W; Doran E; Kerridge I; Day R
    Aust Health Rev; 2014 May; 38(2):160-8. PubMed ID: 24589424
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Australia's pharmaceutical cost sharing policy: reducing waste or affordability?
    Doran E; Robertson J
    Aust Health Rev; 2009 May; 33(2):231-40. PubMed ID: 19563311
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Economic analysis as an aid to subsidisation decisions: the development of Australian guidelines for pharmaceuticals.
    Henry D
    Pharmacoeconomics; 1992 Jan; 1(1):54-67. PubMed ID: 10147039
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Australian pharmaceutical policy: price control, equity, and drug innovation in Australia.
    Doran E; Alexander Henry D
    J Public Health Policy; 2008 Apr; 29(1):106-20. PubMed ID: 18368023
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Retrospective pharmaceutical financial benefits and cost avoidance analysis of clinical trial participation in the Australian haematology setting.
    Truong K; Kwan YL; Nigro L; Huseincehajic A; Trotman J
    Intern Med J; 2019 Sep; 49(9):1092-1098. PubMed ID: 30907047
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmaceuticals in Australia: developments in regulation and governance.
    Lofgren H; Boer Rd
    Soc Sci Med; 2004 Jun; 58(12):2397-407. PubMed ID: 15081192
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.